Common name
ethanamine
IUPAC name
ethanamine
SMILES
CCN
Common name
ethanamine
IUPAC name
ethanamine
SMILES
CCN
INCHI
InChI=1S/C2H7N/c1-2-3/h2-3H2,1H3
FORMULA
C2H7N
Common name
ethanamine
IUPAC name
ethanamine
Molecular weight
45.084
clogP
-0.554
clogS
-0.083
Frequency
0.0677
HBond Acceptor
0
HBond Donor
2
Total PolarSurface Area
26.02
Number of Rings
0
Rotatable Bond
0
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD01559 | Mirabegron |
|
Muscle Relaxants, Genitourinary; Genito Urinary System and Sex Hormones; Drugs for Urinary Frequency and Incontinence; Urological Agents; CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; Adrenergic beta-3 Receptor Agonists; | Mirabegron is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. |
| FDBD01584 | Sofosbuvir |
|
Antiviral Agents; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; | Sofosbuvir is used in combination therapy to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptype 1,2,3, or 4, and to treat HCV and HIV co-infected patients. The combination therapy includes either ribavirin alone or ribavirin and peg-interferon alfa. |
| FDBD01586 | Isoxsuprine |
|
Sympathomimetics; Vasodilator Agents; Tocolytic Agents; Adrenergic beta-Agonists; Cardiovascular System; Peripheral Vasodilators; 2-Amino-1-Phenylethanol Derivatives; | |
| FDBD01592 | Hexoprenaline |
|
Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Tocolytic Agents; Respiratory System; Drugs for Obstructive Airway Diseases; Selective Beta-2-Adrenoreceptor Agonists; Adrenergics, Inhalants; Adrenergics for Systemic Use; | |
| FDBD01609 | Etidocaine |
|
Anesthetics, Local; Anesthetics; Nervous System; Amides; | |
| FDBD01613 | Enviomycin |
|
Anti-Bacterial Agents; Antibiotics, Antitubercular; | |
| FDBD01623 | Articaine |
|
Anesthetics, Local; Anesthetics; Nervous System; Amides; | |
| FDBD01629 | Bromopride |
|
Alimentary Tract and Metabolism; Drugs for Functional Gastrointestinal Disorders; Propulsives; | Bromopride in indicated in the treatment of nausea and vomiting, including PONV (post-operative nausea and vomiting), gastroesophageal reflux disease (GERD/GORD), as well as endoscopy preparation and radiographic studies of the GI tract. |
| FDBD01633 | Aliskiren |
|
Cardiovascular System; Agents Acting on the Renin-Angiotensin System; Renin-Inhibitors; CYP3A4 Inhibitors; | For the treatment of hypertension, to lower blood pressure. |
| FDBD01647 | Ceftolozane |
|
used in combination with metronidazole. |
197 ,
20
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 1hs6_ligand_1_0.mol2 | 1hs6 | 1 | -5.72 | [NH3+]CC | 3 |
| 1utl_ligand_1_0.mol2 | 1utl | 1 | -5.72 | C([NH3+])C | 3 |
| 2i3h_ligand_frag_0.mol2 | 2i3h | 1 | -5.72 | [NH3+]CC | 3 |
| 3b7r_ligand_frag_0.mol2 | 3b7r | 1 | -5.72 | CC[NH3+] | 3 |
| 1b40_ligand_1_13.mol2 | 1b40 | 1 | -5.71 | CC[NH3+] | 3 |
| 1b52_ligand_1_0.mol2 | 1b52 | 1 | -5.71 | C([NH3+])C | 3 |
| 1b7h_ligand_1_1.mol2 | 1b7h | 1 | -5.71 | C([NH3+])C | 3 |
| 1sfi_ligand_1_8.mol2 | 1sfi | 1 | -5.71 | C([NH3+])C | 3 |
1149 ,
115
